RxDoctor Payments Data

Joyce McWhorter

Acute Care · Greer, SCNPI 1184260655

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,639 of the $7,144 with a category attached, or 78.9%. 24 manufacturers reported payments, led by AstraZeneca at 28.0% of the total. 2025 is the largest year on record at $2,926, 2.3 times the $1,264 reported in 2021. Among acute care clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,144in general payments, 2019–2025

Across 144 payments — averaging $49.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Sanofi$2K
  • Johnson & Johnson$364
  • Regeneron Healthcare Solutions, Inc.$328
  • Pulmonx Corporation$328
  • Boehringer Ingelheim$328
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$1,41020%
  • Food & beverage$5,63979%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,144 in reported general payments places this provider in the 90th percentile of 339 acute care providers in South Carolina.

See all acute care providers in South Carolina

Medicare billing

Part B allowed, 2024
$59,398
Medicare patients
522
Services billed
1,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter109$84,016
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$24,193
Stiolto RespimatTiotropium Br/Olodaterol Hcl38$22,986
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$22,488
Breo ElliptaFluticasone/Vilanterol49$21,966
SymbicortBudesonide/Formoterol Fumarate72$21,932
Spiriva RespimatTiotropium Bromide16$14,574
Arnuity ElliptaFluticasone Furoate14$9,326
Albuterol Sulfate HfaAlbuterol Sulfate198$6,424
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$5,450
Varenicline Tartrate11$2,270
Wixela InhubFluticasone Propion/Salmeterol21$2,108
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,894
Ventolin HfaAlbuterol Sulfate13$994
Fluticasone Propionate69$895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$230$139,500212 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,001$44,420101 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$328$37,56154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 acute care providers in South Carolina.

Other acute care in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →